Treatment and management of pseudogout: insights for the clinician
Open Access
- 21 December 2011
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 4 (2), 121-131
- https://doi.org/10.1177/1759720x11432559
Abstract
Pseudogout and the associated calcium pyrophosphate dihydrate (CPPD)- crystal-related arthropathies are common conditions that present particular management problems in clinical practice as they often affect older patients with multiple medical comorbidities. The epidemiology, metabolic and endocrine disease associations, and routine investigations used in the diagnostic workup are briefly reviewed. Current treatment approaches that are mainly directed at relieving the symptoms of joint inflammation are outlined. Unlike gout, there are no agents available that have been shown to decrease crystal load in CPPD-related joint disease. Recent novel insights into the pathogenesis of crystal-induced joint inflammation and subsequent joint degeneration are also discussed. The potential of colchicine as a prophylactic agent in managing recurrent attacks and the likely mechanisms of its effects on the NACHT, LRR and PYD domains-containing protein 3 (NALP-3) inflammasome of the innate immune system are highlighted. The use of agents that directly target the inflammasome, in particular drugs which inhibit the interleukin 1 pathway, in the treatment of severe, refractory pseudogout is also discussed. Finally, there is particular emphasis on the likely pathogenic role of CPPD crystal deposition in degenerative joint disease and the use of targeted anticrystal therapies as potential disease-modifying drugs.Keywords
This publication has 58 references indexed in Scilit:
- Prevalence and Progress of Joint Symptoms in Hereditary Hemochromatosis and Symptomatic Response to VenesectionJCR: Journal of Clinical Rheumatology, 2011
- Calcium deposition in osteoarthritic meniscus and meniscal cell cultureArthritis Research & Therapy, 2010
- The meniscus, calcification and osteoarthritis: a pathologic teamArthritis Research & Therapy, 2010
- Phosphocitrate blocks calcification‐induced articular joint degeneration in a guinea pig modelArthritis & Rheumatism, 2006
- An update on the treatment options for gout and calcium pyrophosphate depositionExpert Opinion on Pharmacotherapy, 2005
- Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides.JCI Insight, 1998
- Comparison of Matrix Vesicles Derived from Normal and Osteoarthritic Human Articular CartilageConnective Tissue Research, 1996
- Localised chondrocalcinosis in unstable joints.BMJ, 1982
- Destructive arthropathy in chondrocalcinosis articularis.Annals Of The Rheumatic Diseases, 1974
- Suppression of metabolic accompaniments of phagocytosis by colchicineArthritis & Rheumatism, 1965